Keywords
Plasma exchange
Thrombotic thrombocytopenic purpura
Submitted : 2023-08-23
Accepted : 2023-09-07
Published : 2023-09-22
Abstract
Objective: To analyze the curative effect of rituximab combined with plasma exchange in the treatment of thrombotic thrombocytopenic purpura. Methods: 70 patients with thrombotic thrombocytopenic purpura that were treated in our hospital from January 2022 to January 2023 were selected for this study. They were divided into two groups according the treatment method they were about to receive. The patients in the control group received plasma exchange. The observation group was given rituximab in addition to plasma exchange. Then, the therapeutic effects of the two groups were observed, and the incidence of adverse reactions was compared. Results: The rate of effectiveness of the treatment received in observation group and the control group was 97.14% and 82.86%, respectively. The treatment received in observation group had a better therapeutic effect (P < 0.05). The incidence of adverse reactions in the observation group (22.86%) was lower than that of the control group (5.71%) , with P < 0.05. Conclusion: Rituximab combined with plasma exchange is relatively more effective than plasma exchange alone, with less adverse reaction, making it a viable treatment option.
References
Yang Y, Sun X, 2021, Effect of Rituximab on Immune Function in Children with Immune Thrombocytopenic Purpura. Electronic Journal of Modern Medicine and Health Research, 5(20): 7–9.
Lan L, Ren J, Yang T, et al., 2020, Observation on the Treatment of Refractory Thrombocytopenic Purpura with Low-Dose Rituximab. Chinese and Foreign Medical Research, 18(28): 14–16.
Gao W, Zhang T, 2019, The Effectiveness of Rituximab in the Treatment of Children with Immune Thrombocytopenic Purpura and its Effect on the Immune Function of Children. Clinical Medicine Research and Practice, 4(30): 110–111 + 121.
Dong S, Zhao Y, 2019, Clinical Effect of Low-Dose Rituximab in the Treatment of Refractory Thrombocytopenic Purpura. Systematic Medicine, 4(15): 1–3 + 59.
Zhu Y, 2019, Clinical Efficacy Analysis of Plasma Exchange Combined with rituximab in the Treatment of Newly Diagnosed Idiopathic Thrombotic Thrombocytopenic Purpura. World Compound Medicine, 5(05): 10–12.
Jiang Y, Ban X, Liu L, 2018, Clinical Efficacy of Plasma Exchange Combined with Rituximab in the Treatment of Newly Diagnosed Idiopathic Thrombotic Thrombocytopenic Purpura. Electronic Journal of Cardiovascular Diseases of Integrated Traditional Chinese and Western Medicine, 6(18): 95–96.
Li J, Chen L, Jiang G, et al., 2021, Efficacy and Safety Analysis of Low Dose Rituximab in the Treatment of Refractory Thrombocytopenia Secondary to Systemic Lupus Erythematosus. Jilin Medicine, 42(4): 966–969.
Dong W, Dai P, Zheng G, et al., 2021, Evaluation of the Curative Effect of Low-Dose Rituximab Combined with Cyclosporine A on Refractory and Recurrent Idiopathic Thrombocytopenic Purpura. China Clinical Research, 34(2): 205–207 + 212.
Wang Y, Rui M, Shang Y, et al., 2021, Economic Evaluation of First-Line Treatment of Adults with Chronic Primary Immune Thrombocytopenia with Dexamethasone Combined with Rituximab. China Pharmacy, 32(24): 3013–3018.
Wang Z, Sun Y, Yan C, et al., 2021, Analysis of the Influence of Donor-Specific Anti-Human Leukocyte Antigen Antibody Levels in Patients with Hematological Diseases Before Haplotype-Identical Hematopoietic Stem Cell Transplantation on Poor Hematopoietic Reconstitution After Rituximab Desensitization Therapy. Chinese Journal of Internal Medicine, 60(7): 644–649.
Cao X, Hu X, Sun Y, et al., 2021, Systematic Review of the Effectiveness and Safety of Eltrombopag Combined with Drug Therapy in Adults with Primary Immune Thrombocytopenia. Journal of Clinical Hematology, 34(7): 495–501.